Home -> Law Blog Directory -> Federal Judiciary Blogs -> Eastern District of Texas Federal Court Practice
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Federal Judiciary
: Eastern District of Texas Federal Court PracticeNew ND Cal Patent Rules
By Michael Smith
Dennis Crouch's Patently-O blog just featured a post by Edward Reines, chair of the ND Cal's local rules advisory committee on that district's new patent rules. The post contains a copy of the new rules and the committee report explaining the changes.
The 2008 revisions include two significant changes, he writes. The first requires the parties to work together to identify the most significant claim terms ("MST"s) in dispute in an attempt to limit the number of terms that need to be construed by the court. Second, the rules eliminate the concept of "preliminary" contentions in favor of a single round of contentions that only be amended for good cause (meaning that the automatic amendment when necessitated by Markman ruling is gone). While the post and the commentary don't emphasize it, however, there seems to me to be a third change, and that is modifying contentions to add additional subjects to be disclosed, such as direct/indirect infringement contentions, obviousness, standing - all issues that I've seen come up in practice recently - to reflect the increasing importance of defensive issues in light of recent caselaw. (One thing I do miss, though, is a redline comparison of the former rules and the new rules - if anyone knows of one, shoot me a copy, would you?)
I haven't studied the new rules in detail yet, but will soon. What do readers think about them? Should the Eastern District of Texas consider adopting some or all of the changes?
Full post as published by Eastern District of Texas Federal Court Practice on February 03, 2008 (boomark / email).
Discouraging Union Organizers
Strict work place rules
VA Sets New Benefit Rules for Agent Orange-Related Ilnesses
Agent Orange-Related Ilnesses VA Sets New Benefit Rules
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
Sony
to Pay $18.5 Million For Patent Infringment

Comments on the Northern District's Local Patent Rules
9th Circuit Modifies Local Patent Rules
PTO Revises Rules of Ethics and Professionalism
Attorneys: New USPTO Patent Appeals Rules Will Raise Costs, Accomplish Little
USPTO Rulemaking Practices Being Called into Question (Again)
Briefs Flying In Patent Office Appeal of Continuation Rules







